Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ...
GlobalData on MSN5d
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlightAs the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
(RTTNews) - Amgen Inc. (AMGN) Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults with generalized myasthenia gravis, a rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback